Santen holds over 40% share in Japan’s ophthalmic drug market and is generating double-digit growth as the #2 player in China, and is one of three fully-diversified ophthalmic drug players.
Santen is still pondering its strategy for the U.S., but could see multiple introductions for retinal disease and glaucoma into the world’s largest ophthalmic drug market over five years.
